Kemik, O.Kemik, A.Sumer, A.Almali, N.Gurluler, E.Gures, N.Tuzun, S.2025-05-102025-05-1020131128-36022-s2.0-84891813346https://hdl.handle.net/20.500.14720/4151Kemik, Ozgur/0000-0002-4612-1428; Gurluler, Ercument/0000-0002-6008-5494BACKGROUND: Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients. PATIENTS AND METHODS: Pre-treatment serum levels of TATI in patients with gastric cancer and healthy controls were analyzed by a specific enzyme-linked immunosorbent assay (ELISA). RESULTS: Statistically significant differences were found in serum TATI levels between patients with gastric cancer and healthy controls (p < 0.0001). There was a significant relationship between the serum levels of TATI and clinicopathological parameters. However, serum levels of TATI were significantly higher in patients with an advanced T stage (T3) (p < 0.001), lymph node metastasis (p < 0.001) and an advanced TNM stage (stage III or IV; p < 0.001). CONCLUSIONS: Our study suggests that TATI may be used to identify potentially high-risk groups of upper gastric carcinoma. Elevated level of TATI was associated with progressive disease or advanced stage.eninfo:eu-repo/semantics/closedAccessTumor-Associated Trypsin InhibitorClinical-Pathological FeaturesGastric CancerArticle1721Q2Q22923292824254562WOS:000328084800014